• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黄热病疫苗接种后的急性嗜内脏性疾病

Acute viscerotropic disease following vaccination against yellow fever.

作者信息

Hayes Edward B

机构信息

Arboviral Diseases Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, CO 80522, USA.

出版信息

Trans R Soc Trop Med Hyg. 2007 Oct;101(10):967-71. doi: 10.1016/j.trstmh.2007.06.013. Epub 2007 Jul 31.

DOI:10.1016/j.trstmh.2007.06.013
PMID:17669451
Abstract

Acute viscerotropic disease following yellow fever vaccination (YEL-AVD) is a rare but serious complication of vaccination with 17D yellow fever vaccine. This paper reviews the existing literature regarding YEL-AVD and discusses possible etiologic mechanisms. A greater understanding of this condition is essential to assuring safe and effective prevention of yellow fever and vaccination against other arboviral diseases for which 17D-based vaccines are being developed.

摘要

黄热病疫苗接种后急性嗜内脏性疾病(YEL-AVD)是接种17D黄热疫苗后一种罕见但严重的并发症。本文回顾了关于YEL-AVD的现有文献,并讨论了可能的病因机制。更深入地了解这种情况对于确保安全有效地预防黄热病以及研发基于17D疫苗的其他虫媒病毒疾病疫苗至关重要。

相似文献

1
Acute viscerotropic disease following vaccination against yellow fever.黄热病疫苗接种后的急性嗜内脏性疾病
Trans R Soc Trop Med Hyg. 2007 Oct;101(10):967-71. doi: 10.1016/j.trstmh.2007.06.013. Epub 2007 Jul 31.
2
Yellow fever-associated viscerotropic disease in Barcelona, Spain.西班牙巴塞罗那的黄热病相关内脏型疾病
J Travel Med. 2008 May-Jun;15(3):202-5. doi: 10.1111/j.1708-8305.2008.00209.x.
3
Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.接种17D黄热病疫苗ARILVAX后出现的嗜内脏性和嗜神经性疾病。
Vaccine. 2004 Jun 2;22(17-18):2103-5. doi: 10.1016/j.vaccine.2004.01.026.
4
Viscerotropic disease following yellow fever vaccination in Peru.秘鲁黄热病疫苗接种后的嗜内脏性疾病。
Vaccine. 2009 Oct 9;27(43):5974-81. doi: 10.1016/j.vaccine.2009.07.082. Epub 2009 Aug 11.
5
Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.2001 - 2002年美国与17D株黄热病疫苗相关的不良事件
MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):989-93.
6
Yellow fever vaccine-associated viscerotropic disease and death in Spain.西班牙的黄热病疫苗相关嗜内脏性疾病及死亡
J Clin Virol. 2006 Jun;36(2):156-8. doi: 10.1016/j.jcv.2006.02.005. Epub 2006 Apr 4.
7
Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.欧洲17D株衍生黄热病疫苗接种不良事件期间的免疫反应。
J Infect Dis. 2008 Jun 1;197(11):1577-84. doi: 10.1086/587844.
8
A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.荷兰一起疑似黄热病疫苗相关内脏疾病病例。
J Travel Med. 2014 Nov-Dec;21(6):421-4. doi: 10.1111/jtm.12135. Epub 2014 Jun 11.
9
[Yellow fever].[黄热病]
Przegl Epidemiol. 2004;58 Suppl 1:101-5.
10
Review of the risks and benefits of yellow fever vaccination including some new analyses.黄热病疫苗接种的风险和益处综述,包括一些新的分析。
Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6.

引用本文的文献

1
Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?老龄化背景下的疾病复发、生产能力问题及安全担忧:是否需要新型黄热病疫苗?
Vaccines (Basel). 2019 Nov 8;7(4):179. doi: 10.3390/vaccines7040179.
2
Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.旅行者与黄热病声明:热带医学与旅行咨询委员会
Can Commun Dis Rep. 2010 Oct 2;36(ACS-11):1-23. doi: 10.14745/ccdr.v36i00a11.
3
STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).
旅行者与黄热病声明:热带医学与旅行咨询委员会(CATMAT)的咨询委员会声明(ACS)
Can Commun Dis Rep. 2013 Mar 5;39(ACS-2):1-20. doi: 10.14745/ccdr.v39i00a02.
4
Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model.恒河猴模型中嗜内脏型黄热病的病理生理学和转录组学分析
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3295. doi: 10.1371/journal.pntd.0003295. eCollection 2014.
5
Comprehensive assessment of serious adverse events following immunization by health care providers.医疗保健人员对免疫接种后严重不良事件的综合评估。
J Pediatr. 2013 Jun;162(6):1276-81, 1281.e1. doi: 10.1016/j.jpeds.2013.01.028. Epub 2013 Feb 26.
6
Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.用于控制沙粒病毒出血热的疫苗平台。
J Vaccines Vaccin. 2012 Nov 20;3(7). doi: 10.4172/2157-7560.1000160.
7
A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.一项随机、双盲、对照临床试验,评估了联合使用免疫球蛋白或安慰剂的 17D 黄热病病毒疫苗:比较病毒血症和免疫原性。
Am J Trop Med Hyg. 2013 Jan;88(1):172-7. doi: 10.4269/ajtmh.2012.12-0179. Epub 2012 Dec 3.
8
Advanced vaccine candidates for Lassa fever.拉沙热的先进疫苗候选物。
Viruses. 2012 Oct 29;4(11):2514-57. doi: 10.3390/v4112514.
9
Methodology for definition of yellow fever priority areas, based on environmental variables and multiple correspondence analyses.基于环境变量和多元对应分析的黄热病优先区域定义方法。
PLoS Negl Trop Dis. 2012;6(7):e1658. doi: 10.1371/journal.pntd.0001658. Epub 2012 Jul 3.
10
Mapping the risk of yellow Fever infection.绘制黄热病感染风险图。
Curr Infect Dis Rep. 2012 Jun;14(3):246-55. doi: 10.1007/s11908-012-0256-6.